Vaccination (IMAGE)

University of Texas at Austin

Vaccination

Caption

An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. A team of researchers, including The University of Texas at Austin's Jason McLellan, report in the journal Science that one dose of their vaccine candidate elicited large increases in RSV-neutralizing antibodies that were sustained for several months.

Credit

iStock

Usage Restrictions

Stock image purchased for use by University of Texas at Austin.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.